![Annick Schwebig](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Annick Schwebig
Directeur/Membre du Conseil chez
INVENTIVA
Fortune : 15 381 $ au 31/05/2026
Profil
Annick Schwebig was the founder of Actelion Pharmaceuticals, Inc. (France) since 2000, serving as Chairman & Chief Executive Officer from 2000 to 2016.
Current jobs include Chairman-Management Board at ESSEC Business School, Vice Chairman-Supervisory Board at INSERM Transfert SA, Director at B Cell Design SAS, Independent Director at Inventiva SA since 2017, and Secretary at Alliance for Research & Innovation in Health Industries.
Former jobs include Vice Chairman-Supervisory Board at INSERM Transfert SA, Director at Diatos SA, Independent Director at Cellectis SA from 2011 to 2023, and GM, VP-Medical Affairs & Research Development at Bristol-Myers Squibb SARL from 1983 to 2000.
Education includes undergraduate and doctorate degrees from Université Paris 1 Panthéon-Sorbonne.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
INVENTIVA SA 0 % | 01/03/2025 | 3 076 ( 0 % ) | 15 381 $ | 31/05/2026 |
Postes actifs de Annick Schwebig
| Sociétés | Poste | Début |
|---|---|---|
| INVENTIVA | Directeur/Membre du Conseil | 01/02/2017 |
Alliance for Research & Innovation in Health Industries | Secrétaire Général | - |
B Cell Design SAS
 B Cell Design SAS Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops innovative products and breakthrough therapeutic concepts for pharma industries | Directeur/Membre du Conseil | - |
ESSEC Business School
 ESSEC Business School Other Consumer ServicesConsumer Services Functions as a College/University | Directeur Général | - |
Anciens postes connus de Annick Schwebig
| Sociétés | Poste | Fin |
|---|---|---|
INSERM Transfert SA
 INSERM Transfert SA Investment ManagersFinance ITSA is an active private equity investment manager focused exclusively on the French biomedical sector, particularly on areas related to INSERM's medical research effort. They favor projects in fields including therapeutic agents, medical devices, diagnostics, tools and technological platforms. The firm invests between EUR 100 and 300 thousand in pre-seed and seed financing. ITSA's investment criteria include sound science, a driven management team, strong IP, a realistic business model with a clearly defined market, and a competitive milestone-driven schedule. They seek to invest in ambitious projects addressing unmet medical needs and potentially leading to dominant market positions. The firm may act as a co-founder, generally sits on the board of their portfolio companies and actively participates in their strategic decisions. | Directeur/Membre du Conseil | - |
| CELLECTIS S.A. | Directeur/Membre du Conseil | 27/06/2023 |
INSERM Transfert SA
INSERM Transfert SA Investment ManagersFinance ITSA is an active private equity investment manager focused exclusively on the French biomedical sector, particularly on areas related to INSERM's medical research effort. They favor projects in fields including therapeutic agents, medical devices, diagnostics, tools and technological platforms. The firm invests between EUR 100 and 300 thousand in pre-seed and seed financing. ITSA's investment criteria include sound science, a driven management team, strong IP, a realistic business model with a clearly defined market, and a competitive milestone-driven schedule. They seek to invest in ambitious projects addressing unmet medical needs and potentially leading to dominant market positions. The firm may act as a co-founder, generally sits on the board of their portfolio companies and actively participates in their strategic decisions. | Directeur/Membre du Conseil | 10/09/2019 |
Actelion Pharmaceuticals, Inc. (France)
 Actelion Pharmaceuticals, Inc. (France) Industrial SpecialtiesProcess Industries Manufactures insulation materials | Directeur Général | 01/01/2016 |
Diatos SA
 Diatos SA Pharmaceuticals: MajorHealth Technology Develops innovative therapies for the treatment of cancer | Directeur/Membre du Conseil | 15/09/2009 |
Formation de Annick Schwebig
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
36
Relations au 1er degré
10
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 10 |
|---|---|
Diatos SA
Diatos SA Pharmaceuticals: MajorHealth Technology Develops innovative therapies for the treatment of cancer | Health Technology |
Actelion Pharmaceuticals, Inc. (France)
Actelion Pharmaceuticals, Inc. (France) Industrial SpecialtiesProcess Industries Manufactures insulation materials | Process Industries |
Cellectis SA
 Cellectis SA Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops immunotherapies | Health Technology |
Université Paris 1 Panthéon-Sorbonne
 Université Paris 1 Panthéon-Sorbonne Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
INSERM Transfert SA
INSERM Transfert SA Investment ManagersFinance ITSA is an active private equity investment manager focused exclusively on the French biomedical sector, particularly on areas related to INSERM's medical research effort. They favor projects in fields including therapeutic agents, medical devices, diagnostics, tools and technological platforms. The firm invests between EUR 100 and 300 thousand in pre-seed and seed financing. ITSA's investment criteria include sound science, a driven management team, strong IP, a realistic business model with a clearly defined market, and a competitive milestone-driven schedule. They seek to invest in ambitious projects addressing unmet medical needs and potentially leading to dominant market positions. The firm may act as a co-founder, generally sits on the board of their portfolio companies and actively participates in their strategic decisions. | Finance |
ESSEC Business School
ESSEC Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Bristol-Myers Squibb SARL
 Bristol-Myers Squibb SARL Medical DistributorsDistribution Services Provides pharmaceutical and health care products | Distribution Services |
B Cell Design SAS
B Cell Design SAS Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company which develops innovative products and breakthrough therapeutic concepts for pharma industries | Commercial Services |
Alliance for Research & Innovation in Health Industries | |
Inventiva SA
 Inventiva SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops oral small molecule therapies for the treatment of MASH and other diseases | Health Technology |
